Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2005
05/12/2005WO2004018502A8 Compounds binding to p-selectin
05/12/2005WO2004000858A3 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
05/12/2005WO2003087159A8 Modulators of the notch signalling pathway and uses thereof in medical treatment
05/12/2005WO2003085124A3 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
05/12/2005WO2003070903A3 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
05/12/2005WO2003012055A3 Sak: modulation of cellular proliferation for treatment of cancer
05/12/2005WO2001079525A3 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
05/12/2005US20050102708 Rodent model generated by continuous infusion of a Fe2+, A beta 42 and buthionine sulfoximine for use as diagnostic and therapeutic screening tool in detection and treatment of alzheimer's disease
05/12/2005US20050101992 Method of Applying Composition To A Surface
05/12/2005US20050101781 Eponemycin and epoxomicin analogs and uses thereof
05/12/2005US20050101773 Genes required for viability and/or reproduction in c. elegans and their use in the development of anti-nematode agents
05/12/2005US20050101770 Humanized recombinant immunoglobulins for use in identifying modulators for prevention and treatment of autoimmune disorders
05/12/2005US20050101769 CD40-interacting and TRAF-interacting proteins
05/12/2005US20050101762 Cyclic peptide for use as tool in transmembrane transport; drug delivery
05/12/2005US20050101677 Prophylaxis and/or reversing presbyopia by applying localized energy to area to be treated and administering biologically acceptable chemical substance capable of breaking chemical bonds such as disulfide bonds between cortical lens fibers
05/12/2005US20050101671 Compounds and compositions for delivering active agents
05/12/2005US20050101664 Anionically coupling an acyl imidazoyl carbamate with a primary amide or carbamate; N-alkylation; inosine-5*-monophosphate dehydrogenase inhibitors
05/12/2005US20050101651 Viricides; protease inbhibitors; useful for inhibiting the activity of picornaviral 3C proteases; for example, 6-carbamoyl-4S-{2S-[(5-naphthalen-1-yl-1H-pyrrole-2-carbonyl)-amino-3-phenyl-propionylamino}-hex-2(trans)-enoic acid ethyl ester
05/12/2005US20050101638 Combination of organic compounds
05/12/2005US20050101565 Using mixture containing pantethine
05/12/2005US20050101558 Antisense modulation of PLML expression
05/12/2005US20050101556 Genetic engineering; Alzheimer's disease; anticancer agents
05/12/2005US20050101555 Antisense modulation of caspase 7 expression
05/12/2005US20050101553 Antisense modulation of calreticulin expression
05/12/2005US20050101540 STAT modulators
05/12/2005US20050101539 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system
05/12/2005US20050101538 particularly Alzheimer's disease and mild cognitive impairment; neurotrophines
05/12/2005US20050101537 Use of exendins and agonists thereof for lowering plasma lipid
05/12/2005US20050101536 Modulation of angiogenesis
05/12/2005US20050101535 Administering hormone inhibitor as therapy for steroid induced obesity
05/12/2005US20050101533 Dried blood factor composition comprising trehalose
05/12/2005US20050101532 Protamine fragment compositions and methods of use
05/12/2005US20050101531 Use of recombinant gelatin-like proteins as plasma expanders and compositions suitable for plasma substitution
05/12/2005US20050101530 Cellular virus receptors and methods of use
05/12/2005US20050101529 Protein modification and maintenance molecules
05/12/2005US20050101527 Method for treating the central nervous system by administration of igf structural analogs
05/12/2005US20050101526 Cyclic peptidomimetic urokinase receptor antagonists
05/12/2005US20050101524 Using arsenic oxide, or complex thereof; angiogenesis inhibitors; anticarcinogenic agents; neurodegenerative agents; antiischemic agents
05/12/2005US20050101523 Antidiabetic agents; therapy for insulin resistance
05/12/2005US20050101520 Administering interferons, tumor necrosis factor antagonist
05/12/2005US20050100990 Factor VIII compositions and methods
05/12/2005US20050100986 Compositions and methods for targeting a polypeptide to the central nervous system
05/12/2005US20050100984 Expression vector comprising nucleotide sequences coding immunoglobulin fusion directed towards tumors for use in treatment and prevention of cell proliferative disorders; tissue targeted therapy; immunotherapy
05/12/2005US20050100982 Factor IX: remodeling and glycoconjugation of factor IX
05/12/2005US20050100963 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
05/12/2005US20050100941 Card-domain containing polypeptides, encoding nucleic acids, and methods of use
05/12/2005US20050100940 Novel FDRG protein and nucleic acid molecules and uses therefor
05/12/2005US20050100918 Mammalian receptor proteins; related reagents and methods
05/12/2005US20050100917 Mammalian receptor proteins; related reagents and methods
05/12/2005US20050100913 RNA interference pathway genes as tools for targeted genetic interference
05/12/2005US20050100912 Nucleotide sequences coding polymerase delta small subunit (POLD2), adipocyte enhancer binding protein 1 (AEBP1) and membrane fusion protein (SNARE) for use in diagnosis, prevention and treatment of osteopenic disorders
05/12/2005US20050100907 Method and medicament for inhibiting the expression of a given gene
05/12/2005US20050100891 Identifying modulators which control endothelial cell and viral gene expression; diagnosis and treatment of cell proliferative disorders; viricides; anticancer agents
05/12/2005US20050100887 Using kinase assay to identify modulators of viral infection; viricides; high throughput assay
05/12/2005US20050100883 Peptide-based diagnostic reagents for SARS
05/12/2005US20050100617 Method for improving age-related physiological deficits and increasing longevity
05/12/2005US20050100611 Administering a therapeutically effective amount of arsenic compounds, optionally along with other non-arsenic therapeutic agents, to a mammal for treating solid tumors
05/12/2005US20050100592 Methods for treatment of human skin damaged by laser treatment or chemical peelings and compositions useful in such methods
05/12/2005US20050100555 Synovial tissue binding peptide; amino acid sequence motifs; identify binding peptides by grafting tissue of first species into second having attenuated immunological response
05/12/2005US20050100554 Chimeric polypeptides, vectors and cells; test for precancerous cells; human papilloma virus
05/12/2005US20050100552 Baculovirus vector, expressed in insect cells; induce apoptosis; introduced into tumor cell by viral vector, liposome, a conjugate, injection, electroporation, particle bombardment
05/12/2005US20050100549 Regulation of cytotrophoblast cell differentiation and cell migration
05/12/2005US20050100548 BAFF, inhibitors thereof and their use in the modulation of B-cell response
05/12/2005US20050100547 Also a method for detecting an agent capable of binding TRAF2 binding site of sphingosine kinase by contacting cells with a putative agent and detecting an altered expression phenotype
05/12/2005US20050100546 Human monoclonal antibodies to epidermal growth factor receptor
05/12/2005US20050100545 Mutated antibody does not possess O-linked glycosylation, nucleic acids encoding prevents N-linked glycosylation; humanized and conjugated with radionucleotide to image target cells
05/12/2005US20050100541 Ligands, including antibodies, showing reactivity against endocrine cells
05/12/2005US20050100540 Platelet-activating factor acetylhydrolase
05/12/2005US20050100539 Enzymes useful for treating and methods for treating MPS-VI and cells lines for producing such enzymes recombinantly
05/12/2005US20050100538 Intradiscal injection of anti-oxidants
05/12/2005US20050100536 Platelet rich plasma, no exogenous activator; sodium bicarbonate buffer, citrate dextrose anticoagulant
05/12/2005US20050100533 Promoting osteodifferentiation by coating a substrate with a solution of a synthetic peptide having -Ile-Ala residues folded in a beta-bend and mimics cell binding by collagen, incorporation into a biocompatible gel, exposure to cells; hard and soft tissue repair; dentistry
05/12/2005US20050100531 Probiotic therapies
05/12/2005US20050100530 Medicinal composition
05/12/2005US20050100529 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione and anti-cancer agent, antibiotic, anti-inflammatory agent, steroid, cytokine, immunosuppressive agent
05/12/2005US20050100519 Glycolic acid, papain, arbutin are hydroxy acids, proteolytic enzymes, skin lightening agents optional to this skin care formulation
05/12/2005DE20023651U1 Aqueous solution formulations, useful for treating viral, tumorous and immune diseases, comprises interferon alpha, buffer system, stabilizing agent, nonionic surfactant, osmotic pressure regulator, and injection water
05/12/2005CA2726967A1 Hydrochloride salts of a glycopeptide phosphonate derivative
05/12/2005CA2551074A1 Hcv ns3-ns4a protease resistance mutants
05/12/2005CA2545499A1 Antagonists of the bradykinin b1 receptor
05/12/2005CA2544731A1 Rapamycin peptides conjugates: synthesis and uses thereof
05/12/2005CA2544473A1 A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
05/12/2005CA2544372A1 A pharmaceutical composition for preventing or treating malignant glioma
05/12/2005CA2544298A1 Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same
05/12/2005CA2544277A1 Keratin gel and the types 2, 4 and 6 of collagens of frog protein for topical use or for lamina preparation use, such as dressing or powdering in food and complements use and in cosmetic mask manufacturing or in solutions used in cosmetic formulation and medical/pharmaceutical
05/12/2005CA2544125A1 Use of ephrins and related molecules to regulate cellular proliferation
05/12/2005CA2543935A1 Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
05/12/2005CA2543763A1 Bacterial virulence factors and uses thereof
05/12/2005CA2543745A1 Methods of organ regeneration
05/12/2005CA2543696A1 Combinations for hcv treatment
05/12/2005CA2543685A1 Neutrophil activation by immune response modifier compounds
05/12/2005CA2543522A1 Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
05/12/2005CA2543255A1 Methods and compositions for regenerating connective tissue
05/12/2005CA2543093A1 Therapeutic regimens for baff antagonists
05/12/2005CA2541856A1 Modified polypeptides with therapeutic activity and methods of use
05/12/2005CA2541846A1 A protein involved in ovarian cancer
05/12/2005CA2540949A1 C-class oligonucleotide analogs with enhanced immunostimulatory potency
05/12/2005CA2538695A1 Clq related protein
05/12/2005CA2537236A1 Anti-angiogenic peptides for treating or preventing endometriosis
05/12/2005CA2534236A1 Lipoparticles comprising proteins, methods of making, and using the same
1 ... 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 ... 3163